The global CAR T-Cell Therapy Agents market size is predicted to grow from US$ 430 million in 2025 to US$ 655 million in 2031; it is expected to grow at a CAGR of 7.3% from 2025 to 2031.
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The 鈥淐AR T-Cell Therapy Agents Industry Forecast鈥� looks at past sales and reviews total world CAR T-Cell Therapy Agents sales in 2024, providing a comprehensive analysis by region and market sector of projected CAR T-Cell Therapy Agents sales for 2025 through 2031. With CAR T-Cell Therapy Agents sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CAR T-Cell Therapy Agents industry.
This Insight Report provides a comprehensive analysis of the global CAR T-Cell Therapy Agents landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on CAR T-Cell Therapy Agents portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global CAR T-Cell Therapy Agents market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CAR T-Cell Therapy Agents and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CAR T-Cell Therapy Agents.
This report presents a comprehensive overview, market shares, and growth opportunities of CAR T-Cell Therapy Agents market by product type, application, key players and key regions and countries.
Segmentation by Type:
CD19-targeted
BCMA-targeted
Segmentation by Application:
Lymphoma
Multiple Myeloma
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics (Pipeline)
CARsgen Therapeutics
Autolus Therapeutics
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Cellectis
Allogene Therapeutics
Celyad
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global CAR T-Cell Therapy Agents 麻豆原创 Size (2020-2031)
2.1.2 CAR T-Cell Therapy Agents 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for CAR T-Cell Therapy Agents by Country/Region (2020, 2024 & 2031)
2.2 CAR T-Cell Therapy Agents Segment by Type
2.2.1 CD19-targeted
2.2.2 BCMA-targeted
2.3 CAR T-Cell Therapy Agents 麻豆原创 Size by Type
2.3.1 CAR T-Cell Therapy Agents 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global CAR T-Cell Therapy Agents 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 CAR T-Cell Therapy Agents Segment by Application
2.4.1 Lymphoma
2.4.2 Multiple Myeloma
2.5 CAR T-Cell Therapy Agents 麻豆原创 Size by Application
2.5.1 CAR T-Cell Therapy Agents 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global CAR T-Cell Therapy Agents 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 CAR T-Cell Therapy Agents 麻豆原创 Size by Player
3.1 CAR T-Cell Therapy Agents 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global CAR T-Cell Therapy Agents Revenue by Player (2020-2025)
3.1.2 Global CAR T-Cell Therapy Agents Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global CAR T-Cell Therapy Agents Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 CAR T-Cell Therapy Agents by Region
4.1 CAR T-Cell Therapy Agents 麻豆原创 Size by Region (2020-2025)
4.2 Global CAR T-Cell Therapy Agents Annual Revenue by Country/Region (2020-2025)
4.3 Americas CAR T-Cell Therapy Agents 麻豆原创 Size Growth (2020-2025)
4.4 APAC CAR T-Cell Therapy Agents 麻豆原创 Size Growth (2020-2025)
4.5 Europe CAR T-Cell Therapy Agents 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa CAR T-Cell Therapy Agents 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas CAR T-Cell Therapy Agents 麻豆原创 Size by Country (2020-2025)
5.2 Americas CAR T-Cell Therapy Agents 麻豆原创 Size by Type (2020-2025)
5.3 Americas CAR T-Cell Therapy Agents 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CAR T-Cell Therapy Agents 麻豆原创 Size by Region (2020-2025)
6.2 APAC CAR T-Cell Therapy Agents 麻豆原创 Size by Type (2020-2025)
6.3 APAC CAR T-Cell Therapy Agents 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe CAR T-Cell Therapy Agents 麻豆原创 Size by Country (2020-2025)
7.2 Europe CAR T-Cell Therapy Agents 麻豆原创 Size by Type (2020-2025)
7.3 Europe CAR T-Cell Therapy Agents 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa CAR T-Cell Therapy Agents by Region (2020-2025)
8.2 Middle East & Africa CAR T-Cell Therapy Agents 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa CAR T-Cell Therapy Agents 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global CAR T-Cell Therapy Agents 麻豆原创 Forecast
10.1 Global CAR T-Cell Therapy Agents Forecast by Region (2026-2031)
10.1.1 Global CAR T-Cell Therapy Agents Forecast by Region (2026-2031)
10.1.2 Americas CAR T-Cell Therapy Agents Forecast
10.1.3 APAC CAR T-Cell Therapy Agents Forecast
10.1.4 Europe CAR T-Cell Therapy Agents Forecast
10.1.5 Middle East & Africa CAR T-Cell Therapy Agents Forecast
10.2 Americas CAR T-Cell Therapy Agents Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 CAR T-Cell Therapy Agents Forecast
10.2.2 Canada 麻豆原创 CAR T-Cell Therapy Agents Forecast
10.2.3 Mexico 麻豆原创 CAR T-Cell Therapy Agents Forecast
10.2.4 Brazil 麻豆原创 CAR T-Cell Therapy Agents Forecast
10.3 APAC CAR T-Cell Therapy Agents Forecast by Region (2026-2031)
10.3.1 China CAR T-Cell Therapy Agents 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 CAR T-Cell Therapy Agents Forecast
10.3.3 Korea 麻豆原创 CAR T-Cell Therapy Agents Forecast
10.3.4 Southeast Asia 麻豆原创 CAR T-Cell Therapy Agents Forecast
10.3.5 India 麻豆原创 CAR T-Cell Therapy Agents Forecast
10.3.6 Australia 麻豆原创 CAR T-Cell Therapy Agents Forecast
10.4 Europe CAR T-Cell Therapy Agents Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 CAR T-Cell Therapy Agents Forecast
10.4.2 France 麻豆原创 CAR T-Cell Therapy Agents Forecast
10.4.3 UK 麻豆原创 CAR T-Cell Therapy Agents Forecast
10.4.4 Italy 麻豆原创 CAR T-Cell Therapy Agents Forecast
10.4.5 Russia 麻豆原创 CAR T-Cell Therapy Agents Forecast
10.5 Middle East & Africa CAR T-Cell Therapy Agents Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 CAR T-Cell Therapy Agents Forecast
10.5.2 South Africa 麻豆原创 CAR T-Cell Therapy Agents Forecast
10.5.3 Israel 麻豆原创 CAR T-Cell Therapy Agents Forecast
10.5.4 Turkey 麻豆原创 CAR T-Cell Therapy Agents Forecast
10.6 Global CAR T-Cell Therapy Agents Forecast by Type (2026-2031)
10.7 Global CAR T-Cell Therapy Agents Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 CAR T-Cell Therapy Agents Forecast
11 Key Players Analysis
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis CAR T-Cell Therapy Agents Product Offered
11.1.3 Novartis CAR T-Cell Therapy Agents Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Novartis Main Business Overview
11.1.5 Novartis Latest Developments
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Information
11.2.2 Gilead Sciences CAR T-Cell Therapy Agents Product Offered
11.2.3 Gilead Sciences CAR T-Cell Therapy Agents Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Gilead Sciences Main Business Overview
11.2.5 Gilead Sciences Latest Developments
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Information
11.3.2 Bristol-Myers Squibb CAR T-Cell Therapy Agents Product Offered
11.3.3 Bristol-Myers Squibb CAR T-Cell Therapy Agents Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Bristol-Myers Squibb Main Business Overview
11.3.5 Bristol-Myers Squibb Latest Developments
11.4 J & J
11.4.1 J & J Company Information
11.4.2 J & J CAR T-Cell Therapy Agents Product Offered
11.4.3 J & J CAR T-Cell Therapy Agents Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 J & J Main Business Overview
11.4.5 J & J Latest Developments
11.5 JW Therapeutics
11.5.1 JW Therapeutics Company Information
11.5.2 JW Therapeutics CAR T-Cell Therapy Agents Product Offered
11.5.3 JW Therapeutics CAR T-Cell Therapy Agents Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 JW Therapeutics Main Business Overview
11.5.5 JW Therapeutics Latest Developments
11.6 FOSUNKite
11.6.1 FOSUNKite Company Information
11.6.2 FOSUNKite CAR T-Cell Therapy Agents Product Offered
11.6.3 FOSUNKite CAR T-Cell Therapy Agents Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 FOSUNKite Main Business Overview
11.6.5 FOSUNKite Latest Developments
11.7 CARsgen Therapeutics (Pipeline)
11.7.1 CARsgen Therapeutics (Pipeline) Company Information
11.7.2 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Agents Product Offered
11.7.3 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Agents Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 CARsgen Therapeutics (Pipeline) Main Business Overview
11.7.5 CARsgen Therapeutics (Pipeline) Latest Developments
11.8 CARsgen Therapeutics
11.8.1 CARsgen Therapeutics Company Information
11.8.2 CARsgen Therapeutics CAR T-Cell Therapy Agents Product Offered
11.8.3 CARsgen Therapeutics CAR T-Cell Therapy Agents Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 CARsgen Therapeutics Main Business Overview
11.8.5 CARsgen Therapeutics Latest Developments
11.9 Autolus Therapeutics
11.9.1 Autolus Therapeutics Company Information
11.9.2 Autolus Therapeutics CAR T-Cell Therapy Agents Product Offered
11.9.3 Autolus Therapeutics CAR T-Cell Therapy Agents Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Autolus Therapeutics Main Business Overview
11.9.5 Autolus Therapeutics Latest Developments
11.10 Sorrento Therapeutics
11.10.1 Sorrento Therapeutics Company Information
11.10.2 Sorrento Therapeutics CAR T-Cell Therapy Agents Product Offered
11.10.3 Sorrento Therapeutics CAR T-Cell Therapy Agents Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Sorrento Therapeutics Main Business Overview
11.10.5 Sorrento Therapeutics Latest Developments
11.11 Mustang Bio
11.11.1 Mustang Bio Company Information
11.11.2 Mustang Bio CAR T-Cell Therapy Agents Product Offered
11.11.3 Mustang Bio CAR T-Cell Therapy Agents Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Mustang Bio Main Business Overview
11.11.5 Mustang Bio Latest Developments
11.12 Bluebird Bio
11.12.1 Bluebird Bio Company Information
11.12.2 Bluebird Bio CAR T-Cell Therapy Agents Product Offered
11.12.3 Bluebird Bio CAR T-Cell Therapy Agents Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Bluebird Bio Main Business Overview
11.12.5 Bluebird Bio Latest Developments
11.13 Cellectis
11.13.1 Cellectis Company Information
11.13.2 Cellectis CAR T-Cell Therapy Agents Product Offered
11.13.3 Cellectis CAR T-Cell Therapy Agents Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Cellectis Main Business Overview
11.13.5 Cellectis Latest Developments
11.14 Allogene Therapeutics
11.14.1 Allogene Therapeutics Company Information
11.14.2 Allogene Therapeutics CAR T-Cell Therapy Agents Product Offered
11.14.3 Allogene Therapeutics CAR T-Cell Therapy Agents Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Allogene Therapeutics Main Business Overview
11.14.5 Allogene Therapeutics Latest Developments
11.15 Celyad
11.15.1 Celyad Company Information
11.15.2 Celyad CAR T-Cell Therapy Agents Product Offered
11.15.3 Celyad CAR T-Cell Therapy Agents Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 Celyad Main Business Overview
11.15.5 Celyad Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
